Trung Huynh
Stock Analyst at UBS
(2.04)
# 964
Out of 5,328 analysts
39
Total ratings
52.17%
Success rate
25.67%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceut... | Maintains: Neutral | 768 633 | 586.15 | 7.99% | 2 | Apr 30, 2025 | |
PFE Pfizer | Maintains: Neutral | 24 25 | 24.03 | 4.04% | 6 | Apr 30, 2025 | |
BMY Bristol-Myers Squibb | Maintains: Neutral | 60 54 | 49.72 | 8.61% | 5 | Apr 11, 2025 | |
CABA Cabaletta Bio | Maintains: Buy | 10 7 | 1.29 | 442.64% | 2 | Apr 1, 2025 | |
INSM Insmed | Maintains: Strong Buy | 105 110 | 72.8 | 51.1% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 38 | 5.46 | 595.97% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 44 | 20.77 | 111.84% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 13 | 2.23 | 482.96% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Strong Buy | 612 710 | 805.81 | -11.89% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 170 175 | 154.53 | 13.25% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 220 200 | 284.76 | -29.77% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 125 126 | 83.39 | 51.1% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 170 | 193.88 | -12.32% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Mar 23, 2021 |